Pacific Standard magazine examines efforts by researchers around the globe to biologically modify bugs to fight human diseases, such as dengue fever. “Biologically altering bugs isn’t entirely new; it’s been done for nearly half a century to protect crops. … It’s only recently, however, that scientists have begun experimenting with using this technology to combat human diseases,” the magazine writes, adding, “If they succeed, they could create an entirely new way of stopping not only dengue but other insect-borne scourges, such as yellow fever, West Nile virus, and malaria. And stopping these diseases has never been more urgent.”
Reuters reports on efforts to develop a vaccine for dengue fever, writing that “victory over … the intensely painful ‘breakbone fever’ … may be in sight.” Paris-based firm Sanofi “hopes for positive results in September from a key trial among children in Thailand that would set it on course to market a shot in 2015, which would prevent an estimated 100 million cases of dengue infection each year,” the news service writes, noting, “Of 20,000 annual deaths, many are of children.” According to Reuters, “Results from that clinical study, in what is known as the Phase IIb of the international standard three-stage process of assessment, are expected in the third quarter” and “will also be presented for scientific scrutiny at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.”
“Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million doses packaged in 10-dose vials,” a Sabin Vaccine Institute press release reports. The study, published in the July 6 issue of the journal Vaccine, “used data on a vaccine developed by U.S. NIH and the facilities of the Instituto Butantan in Sao Paulo, Brazil,” the press release notes, adding the findings “should provide confidence to ministries of health that they can aggressively plan for the inclusion of dengue vaccine in their immunization programs, as the vaccine should be available at a cost that even middle-income and developing countries can afford” (6/27).
“The leading candidate to become the world’s first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world’s population,” the New York Times reports. “Still, the study marked a milestone in the 70-year quest to develop such a vaccine, demonstrating that a safe and effective inoculation against dengue is feasible, researchers reported in a paper published online Monday in the Lancet,” the newspaper adds (Pollack, 9/10). “Tested among just over 4,000 children in rural Thailand who were badly exposed to the mosquito-borne fever, the vaccine had no side effects but only worked against three out of the four dengue strains,” Agence France-Presse writes (9/10).
The Financial Times has published a special report (.pdf) on neglected tropical diseases (NTDs) featuring 10 articles examining issues including prevention, research, and treatment.
The Global Network for Neglected Tropical Diseases’ “End the Neglect” blog reports that the Dengue Vaccine Initiative has launched a redesigned website, including a new blog that “will include regular posts about the disease, dengue in the news, the work of DVI and the development of a dengue vaccine” (9/17).
“The incidence of dengue has grown dramatically around the world in recent decades,” the WHO writes in an updated fact sheet about dengue and severe dengue published on the organization’s website. According to the fact sheet, “Over 2.5 billion people — over 40 percent of the world’s population — are now at risk from dengue,” and “WHO currently estimates there may be 50-100 million dengue infections worldwide every year” (January 2012).
By rendering female Aedes aegypti mosquitoes â€“ the dengue virus vector â€“ unable to fly, scientists say they may be able to slow the spread of the virus which experts believe “affects up to 100 million people a year and threatens over a third of the world’s population,” the BBC reports. Currently, there is no treatment for dengue nor a vaccine to protect against the virus.
“The costs of treating and coping with dengue fever in Puerto Rico total nearly $38 million a year, a new study,” published Wednesday in the American Journal of Tropical Medicine and Hygiene, finds, according to U.S. News & World Report. “It also said that every $1 spent on surveillance and prevention of the mosquito-borne disease could save $5 in illness-related costs,” the news service reports (5/2). “A team of researchers from Brandeis University says households in the U.S. territory pay almost half of that cost, with the government and insurance companies splitting the rest,” the Associated Press/Seattle Times notes (5/2).
Also In Global Health News: African Bank Donates To Global Fund; Dengue-Blocking Mosquitoes; Maternal Health In Afghanistan; Leishmaniasis Drug; HIV/AIDS In Ukraine; Malnutrition In Mozambique; MDR-TB Study
Africa’s Access Bank Donates $1M To Global Fund Africa’s Access Bank “has announced a donation of the sum of $1 million to the Global Fund’s Gift from Africa” project redeemable over a 3-year period (2010 – 2012),” according to the New Times/allAfrica.com. Aigboje Aig-Imoukhuede, Access Bank’s group managing director, said…